{"id":"W4214695698","doi":"10.1007/s12325-022-02068-7","title":"Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Janssen Pharmaceuticals; EMD Serono; Genentech; H. Lundbeck A/S; Biogen; Celgene; Alexion Pharmaceuticals; Bundesministerium für Bildung und Forschung; Teva Pharmaceutical Industries; Sanofi; Deutsche Forschungsgemeinschaft; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Medicine; Glatiramer acetate; Tolerability; Discontinuation; Dimethyl fumarate; Adverse effect; Multiple sclerosis; Internal medicine; Natalizumab; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004168851,0.0006934151,0.001605581,0.000272234,0.0004913002,0.001024093,0.0004800126,0.000974761,0.001600301],"category_scores_gemma":[0.002357928,0.0002126155,0.001912067,0.0003831254,0.000458314,0.0006707467,0.0003617737,0.001685934,0.0003409206],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006048988,"about_ca_system_score_gemma":0.0008059503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009704941,"about_ca_topic_score_gemma":0.002099189,"domain_scores_codex":[0.9989321,0.0004890427,0.00009795528,0.0001786896,0.0001676352,0.0001345381],"domain_scores_gemma":[0.997919,0.000446603,0.0007335879,0.0001772727,0.000205745,0.0005176224],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7302285,0.02119626,0.100315,0.0009337042,0.005448532,0.0003277363,0.0003896135,0.001670521,0.01458646,0.0001617535,0.003479317,0.1212625],"study_design_scores_gemma":[0.2591159,0.3993267,0.3197702,0.0001404776,0.006088267,0.001093873,0.0001885272,0.001662469,0.008054007,0.0003049326,0.004154522,0.00009989495],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941227,0.002476705,0.0001874027,0.0001259844,0.00002363442,0.0004189919,0.001334299,0.00003230809,0.001278119],"genre_scores_gemma":[0.9946393,0.0007534207,0.0004338915,0.0003630565,0.0000594849,0.0003006424,0.002815986,0.00001072498,0.0006234737],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004168851,"threshold_uncertainty_score":0.02204728,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03422665416530311,"score_gpt":0.3606155336236517,"score_spread":0.3263888794583485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}